We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CDTX market cap is 1.07B. The company's latest EPS is USD -0.2536 and P/E is -46.57.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 40.74M | 10.22M | 25.99M | 7.61M | 12.72M |
| Operating Income | 14.92M | -13.27M | 2.98M | -12.83M | -8.56M |
| Net Income | 14.98M | -13.38M | 2.53M | -11.68M | -8.17M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 20.92M | 12.07M | 49.57M | 64.29M | 63.91M |
| Operating Income | -41.72M | -71.85M | -42.26M | -29.72M | -24.48M |
| Net Income | -41.09M | -74.87M | -42.47M | -29.8M | -22.93M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 66.86M | 47.59M | 81.74M | 67.99M | 63.47M |
| Total Liabilities | 57.79M | 50.5M | 54.9M | 52.57M | 55.43M |
| Total Equity | 9.07M | -2.9M | 26.84M | 15.41M | 8.04M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 68.98M | 60.42M | 75.33M | 47.59M | 67.03M |
| Total Liabilities | 31.14M | 49.71M | 53.75M | 50.5M | 75.24M |
| Total Equity | 37.84M | 10.72M | 21.57M | -2.9M | -8.21M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -7.47M | -28.47M | -10.9M | -8.08M | -9.71M |
| Investing | -109k | -118k | -94k | -201k | -327k |
| Financing | -1.62M | -951k | 26.24M | 25.98M | 25.98M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -28.53M | -54.41M | -25.23M | -28.47M | -22.43M |
| Investing | -35k | -186k | -41k | -118k | -505k |
| Financing | 14.27M | 37.28M | 44.6M | -951k | 25.98M |
| Market Cap | 1.07B |
| Price to Earnings Ratio | -46.57 |
| Price to Sales Ratio | 16.71 |
| Price to Cash Ratio | 29.85 |
| Price to Book Ratio | -130.09 |
| Dividend Yield | - |
| Shares Outstanding | 90.43M |
| Average Volume (1 week) | 287.56k |
| Average Volume (1 Month) | 1.03M |
| 52 Week Change | -42.11% |
| 52 Week High | 29.60 |
| 52 Week Low | 10.004 |
| Spread (Intraday) | 0.29 (2.46%) |
| Company Name | Cidara Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.cidara.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
